Please login to the form below
Crucell
This page shows the latest Crucell news and features for those working in and with pharma, biotech and healthcare.
Janssen’s quest to prevent diseases taking hold
Janssen’s acquisition of Crucell in 2011 brought it a suite of promising platforms covering HIV, a universal flu vaccine, respiratory syncytial virus (RSV), which is an infection of the lungs
Latest news
-
Ebola vaccine halt 'a precaution' say researchers
Meanwhile, Johnson &Johnson (J&J) is also stepping up production of its own candidate - being developed by subsidiary Crucell in partnership with the Danish biotech Bavarian Nordic and the US National
-
J&J to produce one million doses of Ebola vaccine
The vaccine is being developed by J&J's Netherlands-based subsidiary Crucell in partnership with the Danish biotech Bavarian Nordic and the US National Institutes of Health (NIH). ... It combines Crucell's AdVac technology and Bavarian Nordi's MVA-BN
-
J&J fast-tracks Ebola vaccine
The US-based healthcare giant's subsidiary Crucell – based in the Netherlands – is collaborating with the Danish biotech Bavarian Nordic on a combination vaccine regimen with clinical trials in humans planned ... So far the regimen – which combines
-
Janssen boosts vaccines pipeline with GlycoVaxyn deal
Its early development will see GlycoVaxyn collaborate with Janssen's vaccines- focused affiliate Crucell, but once the programme enters later-stage clinical studies, Janssen will take over development and then lead
-
J&J complete acquisition of Crucell
As a result of the deal, Crucell will become the centre for vaccines within the J&J group. ... In October 2010, J&J reached an agreement with Crucell on its 24.75 a share purchase offer.
Ebola vaccine halt 'a precaution' say researchers
J&J to produce one million doses of Ebola vaccine
More from news
Approximately 1 fully matching, plus 20 partially matching documents found.
Latest appointments
-
Kiadis Pharma appoints new chief operations officer
Prior to his time at Janssen, Feijen held positions for the likes of Crucell, Avebe and Gist Brocades.
-
Cell Medica adds to senior management team
He brings extensive experience in biotechnology manufacturing to the role, having held senior leadership positions at Crucell, Merck, Roche and Schering-Plough.
-
TiGenix appoints Dr Marie Paule Richard
She takes on role as chief medical officer and brings experience from Aicuris and Crucell. ... pharmacovigilance and medical affairs at Crucell in Switzerland.
Kiadis Pharma appoints new chief operations officer
Cell Medica adds to senior management team
TiGenix appoints Dr Marie Paule Richard
More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Digital project manager
-
Competitive
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
-
Digital account director
-
Competitive
- Client Services Director +, Remote or London – Leadership Opport...
-
Highly Competitive Salary, Bonus &Benefits
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
-
Digital strategist
-
Competitive
- FREELANCE (Outside IR35) Opportunities for this week below!!!
-
Superb Day Rate
- Israel study suggests Pfizer/BioNTech vaccine is less effective against Delta variant
- Bayer’s BlueRock Therapeutics gains FDA fast track for Parkinson’s disease cell therapy
- GSK reveals plans for £400m R&D facility expansion in England
- FDA advisory committee votes against approval of AZ, FibroGen's roxadustat
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- Novartis highlights potential of its radioligand therapy in prostate cancer at ASCO
- Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader
- Roche engaged in talks with FDA for Alzheimer’s drug candidate
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- The future of work has been just around the corner for some time...
- Investigating the Complexities of the Canadian & Global Health Systems
- Impetus Digital Overview
- Onyx Health Launch Creative Studio After Record Year
- BioNTech plans acquisition of Kite’s TCR cell therapy R&D platform
- Tyson Fury takes on his Invisible Opponent in hard hitting ad for suicide prevention charity Campaign Against Living Miserably
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Novo Nordisk signs deal for Prothena's heart drug worth up to $1.2bn
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
PMHub
Madmicrobe Studios - Medical Animation
MadMicrobe is an award-winning team of certified medical illustrators creating animations that engage your audience with immersive experiences that bring...
Latest intelligence
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
- The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
- Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
- Virtual Speaker Program: A Customer Story
- Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....
